Tassos Perrakis
@tassosperrakis.bsky.social
On BlueSky I am a research scientist with a passion for the structure and mechanism of macromolecules - but at Instagram I cook and at Facebook I am into Greek politics.
Check out our #AHMPC site that got a brand new tool! You can now browse complexes by their relationship to GO terms or disease association! ahmpc.eu/cluster.html
Complexity
ahmpc.eu
September 17, 2025 at 3:18 PM
Check out our #AHMPC site that got a brand new tool! You can now browse complexes by their relationship to GO terms or disease association! ahmpc.eu/cluster.html
Featuring #AlphaBridge features from @alvarezsalmoral.bsky.social, with @jonasteuwen.bsky.social and team, our new work from @nkinl.bsky.social nl.bsky.social @oncodeinstitute.bsky.social . Have a look at ahmpc.eu for more!
Integrating computational protein structure predictions and genetic dependencies yields an atlas of human multi-protein complexes (AHMPC) https://www.biorxiv.org/content/10.1101/2025.09.09.675133v1
September 13, 2025 at 12:27 PM
Featuring #AlphaBridge features from @alvarezsalmoral.bsky.social, with @jonasteuwen.bsky.social and team, our new work from @nkinl.bsky.social nl.bsky.social @oncodeinstitute.bsky.social . Have a look at ahmpc.eu for more!
Reposted by Tassos Perrakis
Integrating computational protein structure predictions and genetic dependencies yields an atlas of human multi-protein complexes (AHMPC) https://www.biorxiv.org/content/10.1101/2025.09.09.675133v1
September 13, 2025 at 3:45 AM
Integrating computational protein structure predictions and genetic dependencies yields an atlas of human multi-protein complexes (AHMPC) https://www.biorxiv.org/content/10.1101/2025.09.09.675133v1
Reposted by Tassos Perrakis
Integrating computational protein structure predictions and genetic dependencies yields an atlas of human multi-protein complexes (AHMPC) https://www.biorxiv.org/content/10.1101/2025.09.09.675133v1
September 13, 2025 at 3:45 AM
Integrating computational protein structure predictions and genetic dependencies yields an atlas of human multi-protein complexes (AHMPC) https://www.biorxiv.org/content/10.1101/2025.09.09.675133v1
7/11 onwards, the best bit ☺️
Read the whole thread by @daaninthelab.bsky.social : a power walk to a great adventure! Very proud of her and @rborza.bsky.social and the whole team!
Read the whole thread by @daaninthelab.bsky.social : a power walk to a great adventure! Very proud of her and @rborza.bsky.social and the whole team!
CryoEM analysis of the Zincore bound to ZFP91 onto the DNA revealed a striking complex: instead of recognising an effector domain, Zincore binds to multiple DNA-bound ZNF domains directly, which revealed two peculiarities: 7/11 @rborza.bsky.social @tassosperrakis.bsky.social
July 4, 2025 at 11:57 AM
7/11 onwards, the best bit ☺️
Read the whole thread by @daaninthelab.bsky.social : a power walk to a great adventure! Very proud of her and @rborza.bsky.social and the whole team!
Read the whole thread by @daaninthelab.bsky.social : a power walk to a great adventure! Very proud of her and @rborza.bsky.social and the whole team!
Reposted by Tassos Perrakis
In today’s publication in Science we introduce Zincore: a novel protein of QRICH1 and SEPHS1 and functions as a transcriptional coregulator dedicated to zinc finger transcription factors. Here’s how we found it: 🧵 www.science.org/doi/10.1126/... 1/11
Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression
Zinc finger proteins (ZNFs) are the largest family of transcription factors, yet how they activate gene expression remains unclear. In this study, we identified Zincore, a protein complex consisting o...
www.science.org
July 4, 2025 at 11:00 AM
In today’s publication in Science we introduce Zincore: a novel protein of QRICH1 and SEPHS1 and functions as a transcriptional coregulator dedicated to zinc finger transcription factors. Here’s how we found it: 🧵 www.science.org/doi/10.1126/... 1/11
Reposted by Tassos Perrakis
🚨New Article Out!!
📢 In our latest work, we propose a Three-Point Lock binding mode for ATX inhibitors 🔒
🚀 This approach may represent the final piece in the puzzle of known binding mode types — and could have therapeutic relevance
♥️ Thanks for your support
Read more here: doi.org/10.1016/j.bm...
📢 In our latest work, we propose a Three-Point Lock binding mode for ATX inhibitors 🔒
🚀 This approach may represent the final piece in the puzzle of known binding mode types — and could have therapeutic relevance
♥️ Thanks for your support
Read more here: doi.org/10.1016/j.bm...
April 15, 2025 at 11:24 PM
🚨New Article Out!!
📢 In our latest work, we propose a Three-Point Lock binding mode for ATX inhibitors 🔒
🚀 This approach may represent the final piece in the puzzle of known binding mode types — and could have therapeutic relevance
♥️ Thanks for your support
Read more here: doi.org/10.1016/j.bm...
📢 In our latest work, we propose a Three-Point Lock binding mode for ATX inhibitors 🔒
🚀 This approach may represent the final piece in the puzzle of known binding mode types — and could have therapeutic relevance
♥️ Thanks for your support
Read more here: doi.org/10.1016/j.bm...
Dr. Ida de Vries!
April 5, 2025 at 11:07 AM
Dr. Ida de Vries!
February 28, 2025 at 5:30 PM
Very happy for my collaborator at the @embl.org Grenoble who led the microdiffractometer engineering project! Very well deserved prize.
Congratulations, Irma Querques and Florent Cipriani!
The two are the recipients of the 2025 EMBL alumni awards, in recognition of their outstanding contributions to genome engineering and structural biology instrumentation, respectively.
www.embl.org/news/awards-...
The two are the recipients of the 2025 EMBL alumni awards, in recognition of their outstanding contributions to genome engineering and structural biology instrumentation, respectively.
www.embl.org/news/awards-...
Announcing the 2025 EMBL Alumni Award recipients | EMBL
Two EMBL alumni have been recognised for their outstanding contributions to genome engineering and structural biology instrumentation
www.embl.org
February 19, 2025 at 10:01 PM
Very happy for my collaborator at the @embl.org Grenoble who led the microdiffractometer engineering project! Very well deserved prize.
This will go well.
February 19, 2025 at 8:15 PM
This will go well.
An opinion piece by @wouterhm.bsky.social , featuring ideas from all authors which are beautifully illustrated by @rborza.bsky.social : Unlocking the signaling potential of GPI-anchored proteins through lipolytic cleavage www.cell.com/trends/cell-...
January 24, 2025 at 4:02 PM
An opinion piece by @wouterhm.bsky.social , featuring ideas from all authors which are beautifully illustrated by @rborza.bsky.social : Unlocking the signaling potential of GPI-anchored proteins through lipolytic cleavage www.cell.com/trends/cell-...
Reposted by Tassos Perrakis
I’m looking for a postdoc to join my team under a recently funded ERC Starting Grant.
If you’re passionate about structural #virology and have experience in #cryoEM SPA and/or #cryoET, get in touch!
Application deadline: January 19th.
Please share with your networks 🙏
Job link: tiny.cc/7v33001
If you’re passionate about structural #virology and have experience in #cryoEM SPA and/or #cryoET, get in touch!
Application deadline: January 19th.
Please share with your networks 🙏
Job link: tiny.cc/7v33001
Postdoctoral Researcher in Structural Virology
This project is focused on deciphering the role of virally encoded AAA+ ATPases in the replication cycles of Enteroviruses and Noroviruses.
tiny.cc
December 27, 2024 at 7:59 AM
I’m looking for a postdoc to join my team under a recently funded ERC Starting Grant.
If you’re passionate about structural #virology and have experience in #cryoEM SPA and/or #cryoET, get in touch!
Application deadline: January 19th.
Please share with your networks 🙏
Job link: tiny.cc/7v33001
If you’re passionate about structural #virology and have experience in #cryoEM SPA and/or #cryoET, get in touch!
Application deadline: January 19th.
Please share with your networks 🙏
Job link: tiny.cc/7v33001
New features in #AlphaBridge implemented by @alvarezsalmoral.bsky.social
🟥 Customisable cutoff-level for filtering on weak (0.5) or strong (0.9) interactions.
🟦 Displaying the ipTM score, and the brand-new "Contact-ipTM and #AlphaBridge scores.
🟧 Per-interface #AlphaBridge scores.
🟥 Customisable cutoff-level for filtering on weak (0.5) or strong (0.9) interactions.
🟦 Displaying the ipTM score, and the brand-new "Contact-ipTM and #AlphaBridge scores.
🟧 Per-interface #AlphaBridge scores.
December 19, 2024 at 2:48 PM
New features in #AlphaBridge implemented by @alvarezsalmoral.bsky.social
🟥 Customisable cutoff-level for filtering on weak (0.5) or strong (0.9) interactions.
🟦 Displaying the ipTM score, and the brand-new "Contact-ipTM and #AlphaBridge scores.
🟧 Per-interface #AlphaBridge scores.
🟥 Customisable cutoff-level for filtering on weak (0.5) or strong (0.9) interactions.
🟦 Displaying the ipTM score, and the brand-new "Contact-ipTM and #AlphaBridge scores.
🟧 Per-interface #AlphaBridge scores.
Few years ago, our collaborators on the "base J" project identified the JBP3 protein. We had determined the crystal structure of the DNA-binding domain, but we could never make sense of the cryo-EM reconstructions of full-length JBP3: nice single particles, but AlphaFold models did not fit the maps.
December 18, 2024 at 10:27 AM
Few years ago, our collaborators on the "base J" project identified the JBP3 protein. We had determined the crystal structure of the DNA-binding domain, but we could never make sense of the cryo-EM reconstructions of full-length JBP3: nice single particles, but AlphaFold models did not fit the maps.
Reposted by Tassos Perrakis
Thrilled to present Alphabridge in the Computational Chemistry session at #NWOChains! We aim to facilitate researchers to analyze interacting interfaces in predicted biomolecular structures. Honored to share insights with top chemists in the Netherlands. 🚀🔬 Preprint: www.biorxiv.org/content/10.1...
December 4, 2024 at 4:23 PM
Thrilled to present Alphabridge in the Computational Chemistry session at #NWOChains! We aim to facilitate researchers to analyze interacting interfaces in predicted biomolecular structures. Honored to share insights with top chemists in the Netherlands. 🚀🔬 Preprint: www.biorxiv.org/content/10.1...
Greece got exactly 0 ERC consolidator grants this year.
0 grants to mid-career outstanding scientists for curiosity driven research at the highest level.
Maybe a statistical fluke?
Or a result of chronic national underfunding, insane bureaucracy, unfairness, opacity, nepotism, and low income?
0 grants to mid-career outstanding scientists for curiosity driven research at the highest level.
Maybe a statistical fluke?
Or a result of chronic national underfunding, insane bureaucracy, unfairness, opacity, nepotism, and low income?
December 4, 2024 at 6:37 AM
Greece got exactly 0 ERC consolidator grants this year.
0 grants to mid-career outstanding scientists for curiosity driven research at the highest level.
Maybe a statistical fluke?
Or a result of chronic national underfunding, insane bureaucracy, unfairness, opacity, nepotism, and low income?
0 grants to mid-career outstanding scientists for curiosity driven research at the highest level.
Maybe a statistical fluke?
Or a result of chronic national underfunding, insane bureaucracy, unfairness, opacity, nepotism, and low income?
Surely you have been using AlphaFold3 for your research project? If so, have you considered #AlphaBridge to analyze the output for macromolecule complexes prediction?
Web server: alpha-bridge.eu
Preprint: www.biorxiv.org/content/10.1...
New features coming soon!
Web server: alpha-bridge.eu
Preprint: www.biorxiv.org/content/10.1...
New features coming soon!
December 3, 2024 at 1:53 PM
Surely you have been using AlphaFold3 for your research project? If so, have you considered #AlphaBridge to analyze the output for macromolecule complexes prediction?
Web server: alpha-bridge.eu
Preprint: www.biorxiv.org/content/10.1...
New features coming soon!
Web server: alpha-bridge.eu
Preprint: www.biorxiv.org/content/10.1...
New features coming soon!
Reposted by Tassos Perrakis
📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: bit.ly/3O4bOjq
November 29, 2024 at 8:36 AM
📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: bit.ly/3O4bOjq
Today, a cancer patient advocate claimed that: ‘There is excellent research but not enough translation.’ While I appreciate the sentiment, I disagree profoundly. The issue isn’t just about translation—it’s that we don’t yet have enough excellent research to identify what will truly impact patients.
November 28, 2024 at 5:09 PM
Today, a cancer patient advocate claimed that: ‘There is excellent research but not enough translation.’ While I appreciate the sentiment, I disagree profoundly. The issue isn’t just about translation—it’s that we don’t yet have enough excellent research to identify what will truly impact patients.
An excellent talk by @andreasbender.bsky.social on the real (and often overstated) impact of AI in drug discovery, offering balanced insights that cut through the hype, along with valuable ideas and suggestions for improvement.
November 28, 2024 at 1:12 PM
An excellent talk by @andreasbender.bsky.social on the real (and often overstated) impact of AI in drug discovery, offering balanced insights that cut through the hype, along with valuable ideas and suggestions for improvement.
Reposted by Tassos Perrakis
Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX
November 27, 2024 at 4:45 PM
Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX